Scouted: I Tried Prolon's 5-Day ‘Fasting-Mimicking' Program and Lived to Tell the Tale
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission.
Like many food lovers, the word 'fasting' has always intimidated me—especially since I've committed to exercising consistently in 2025. When I saw a food influencer post about Prolon's 'Fasting Mimicking' Nutrition program last year, I was instantly intrigued—particularly because she said she felt amazing during the entire five-day program. At the start of the new year, I was looking for a reset, but juice cleanses, and caffeine-free programs were a hard pass for me. Prolon's program promises to deliver the benefits of fasting (we'll get into that later) while still allowing you to eat a small amount of solids and liquids. Essentially, the low-calorie diet tricks your body into thinking it's fasting, letting you reap the benefits without severe caloric restriction.
Dr. Valter Longo, founder of L-Nutra and creator of the Fasting Mimicking Diet (FMD), developed the nutrition program to help patients lose weight and, more importantly, reduce cholesterol, lower age-related disease risk, boost metabolic health, and promote longevity. Prolon's program has also been clinically tested by the laboratory of Dr. Longo and Keck Hospital at the University of Southern California, which is a big deal—something many other fasting programs and cleanses can't claim.
The super-structured program comes in one-day and five-day options. After the indulgent holiday season, I opted for the five-day reset. Proponents of the five-day diet (and the brand) say that in addition to helping you shed a few pounds, the FMD may support longevity by stimulating autophagy (inner cellular rejuvenation). Opponents argue there isn't enough data to support these claims and suggest that sending your body into starvation mode may not be as effective for long-term health as consistently eating whole foods. As a neutral observer, I decided to test the five-day program to see what happened.
When I opened the box, I was pleasantly surprised by the organization. It contains five separate boxes for each day, each filled with your 'meals' and supplements. The meals come in the form of plant-based soups, bars, snacks, specific drinks, and supplements. You're also allowed unlimited water and one cup of black coffee (minus the creamer) per day. Personally, I wouldn't give up caffeine for anything, so this was a huge plus for me. Each day, you're consuming around 700 to 1,000 calories, depending on the day.
The box also includes a 'menu' that outlines everything you'll eat (and are allowed to drink) for each day. Day one was the easiest since I hadn't fasted the day before, and the program kicked off with a higher-calorie day. Days three and five were definitely the hardest—and based on other reviews, I wasn't alone—because you're only getting about 700 calories, and you don't get your end-of-day 'treat,' the Choco Crisp L-Bar.
Each day starts with a nut-forward bar, which is pretty satisfying and helps keep you full. Lunch is usually a soup of some sort, and in the afternoon, on three of the days, you get either kale and almond crackers or a pack of olives. Dinner is another soup, and on days one and two, you get a small 'dessert.' You're also given a glycerin liquid to mix with water, which 'provides the body with an alternate energy source to use instead of lean body mass during days 2-5 of the fast,' as well as several herbal tea bags. Again, the unlimited water and tea, plus one cup of black coffee, were my saving grace.
It's not the best food I've ever had, but I didn't expect it to be. I was surprised by how good some of the soups, crackers, and olives were. I expected to feel famished and repulsed by the soups' flavor (or lack thereof). While I definitely wouldn't choose the Carrot Ginger soup again, I really enjoyed the Green Pea and Chives and Lentil Curry soups and would eat them even if I wasn't on the FMD diet. The kale and almond crackers and olive packs were also delicious.
I'm already hunting for alternatives on Amazon and Costco so I can enjoy them every day. I was also impressed by the creamy consistency of the soups. I had imagined they'd be chalky (like some powdered greens supplements), but they weren't at all.
In theory, yes. In fact, the brand suggests you maintain your normal lifestyle as much as possible while on the program. However, I kept my workouts low-impact (i.e., walking) and skipped my usual heated Pilates fusion classes and weight training. These classes are heated to 105°F and combine bursts of cardio and HIIT. I was worried about feeling faint, and they significantly increased my appetite. With brisk walks on an incline for three of the five days, I felt OK (I skipped days three and five because I was more tired and lightheaded).
By day six, I had lost five pounds. While most of this was likely water weight, I haven't regained it yet. I attribute this to the transition diet (days six and seven), which is recommended after the program. The brand suggests slowly introducing easy-to-digest foods like beans, grains, and lean protein in the two days following completion. Despite the significant caloric reduction, I didn't feel as exhausted and malnourished as I'd anticipated. The third and fifth days were challenging, but that was mostly due to temptation from others around me who weren't doing the cleanse. If you follow a lot of food influencers or enjoy reading restaurant reviews, I recommend taking a break from this during the program. Trust me, watching TikToks of Mukbangs and food reviews will test your willpower. I learned this the hard way.
Another concern I had was how the reduced calories would impact my sleep. I typically don't sleep well when I don't eat a good dinner, and I tend to eat later than most. I can't go to bed hungry and still function the next day, especially with only one cup of coffee. Fortunately, like many others, my sleep was OK. The fifth night was rough, and my Oura Ring called me out for my lack of 'readiness,' but I figured one night of subpar sleep was worth the other benefits. Plus, I didn't feel sluggish or zombified the next day, which I attribute to the FMD benefits.
This was much more manageable than I expected, and I will definitely do another five-day program before summer.
It's important to note that Prolon is not for everyone, especially athletes, those with eating disorders, or individuals with certain health conditions. It's always recommended to consult your physician or healthcare provider before starting a new diet or lifestyle shift.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


San Francisco Chronicle
15 hours ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.


Fox News
2 days ago
- Fox News
New mobile robot helps seniors walk safely and prevent falls
The demographic landscape in the U.S. is shifting rapidly, with the median age now at 38.9, almost a decade older than it was in 1980. By 2050, the population of adults over 65 is projected to surge from 58 million to 82 million, intensifying the already urgent challenge of eldercare. With falls remaining the top cause of injury among older adults, the need for innovative, tech-driven solutions has never been clearer. MIT engineers are stepping up to this challenge with E-BAR, a mobile robot designed to physically support seniors and prevent falls as they move around their homes. E-BAR, short for Elderly Bodily Assistance Robot, is not your typical assistive device. Rather than relying on harnesses or wearables, which many seniors find cumbersome or stigmatizing, E-BAR operates as a set of robotic handlebars that follow users from behind. This allows individuals to walk freely, lean on the robot's arms for support or receive full-body assistance when transitioning between sitting and standing. The robot's articulated body, constructed from 18 interconnected bars, mimics the natural movement of the human body, delivering a seamless and intuitive experience. The engineering behind E-BAR's mobility is equally impressive. The robot's 220-pound base is meticulously designed to support the weight of an average adult without tipping or slipping, and its omnidirectional wheels enable smooth navigation through tight spaces and around household obstacles. This means E-BAR can move effortlessly alongside users, providing support in real time, whether they are reaching for a high shelf or stepping out of a bathtub. What sets E-BAR apart from previous eldercare robots is its integrated fall-prevention system. Each arm is embedded with airbags made from soft, grippable materials that can inflate instantly if a fall is detected. This rapid response cushions the user without causing bruising, and, crucially, it does so without requiring the user to wear any special gear. In lab tests, E-BAR successfully supported elderly volunteers as they performed everyday tasks that often pose a risk for falls, such as bending down, stretching up or navigating the tricky edge of a bathtub. Currently, E-BAR is operated via remote control, but the MIT team is already working on automating its navigation and assistance features. The vision is for future versions to autonomously follow users, assess their real-time fall risk using machine learning algorithms and provide adaptive support as their mobility needs evolve. The E-BAR project is rooted in extensive interviews with seniors and caregivers, which revealed a strong preference for unobtrusive, non-restrictive support systems. E-BAR's U-shaped handlebars leave the front of the user completely open, allowing for a natural stride and easy exit at any time. The robot is slim enough to fit through standard doorways and is designed to blend into the home environment, making it a practical addition rather than an intrusive medical device. MIT researchers see E-BAR as part of a broader ecosystem of assistive technologies, each tailored to different stages of aging and mobility. While some devices may offer predictive fall detection or harness-based support, E-BAR's unique combination of full-body assistance, fall prevention and user autonomy addresses a critical gap for those who want to maintain independence but need occasional support. Currently, MIT's E-BAR robot is still in the prototype stage and is not yet available for consumer purchase. The research team is continuing to refine the design and aims to bring it to market in the coming years, but it could take 5–10 years before the device receives full regulatory approval and becomes commercially accessible. Looking forward, the research team is also focused on refining E-BAR's design to make it slimmer, more maneuverable and even more intuitive to use. They are also exploring ways to integrate advanced AI for real-time fall prediction and adaptive assistance, ensuring that the robot can meet users' changing needs as they age. The ultimate goal is to provide seamless, continuous support, empowering seniors to live safely and confidently in their own homes. What stands out about E-BAR is how it's designed with real people in mind, not just as a tech gadget. It's easy to see how something like this could make a big difference for seniors wanting to stay independent without feeling tied down by bulky or uncomfortable devices. As the technology improves, it could change the way we think about caring for older adults, making everyday life safer and a bit easier for everyone involved. How comfortable would you feel trusting a robot like E-BAR to help your loved ones move safely around their home? Let us know by writing us at For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Follow Kurt on his social channels: Answers to the most-asked CyberGuy questions: New from Kurt: Copyright 2025 All rights reserved.
Yahoo
2 days ago
- Yahoo
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company's umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain. Details of the oral presentation are as follows: Abstract Title: Rationale and Study Design for a Phase 2/3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess Safety and Efficacy of Allogeneic Umbilical Cord Lining Stem Cells on Disease Severity and Steroid Tapering in Participants with Idiopathic Inflammatory Myopathy Abstract Number: OP0318 Session Title: Clinical Abstract Sessions: Novelties and innovative therapeutic strategies in inflammatory myopathies Session Date and Time: Friday, June 13, 2025, 10:30 AM CEST About Idiopathic Inflammatory Myopathy (IIM) Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM. Polymyositis causes inflammation and weakness of the skeletal muscles responsible for movement. Dermatomyositis is a form of polymyositis that is associated with skin rash, in addition to muscle inflammation. Both disorders can significantly compromise the quality of life and are very challenging to treat. Currently, the only treatment for these disorders is immunosuppressive drugs, which can be associated with significant toxicity and other side effects. About RESTEM RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we are advancing two potentially groundbreaking programs, Restem-L, our umbilical-lining modified progenitor cells (UMPC) program for autoimmune diseases; and our activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are uniquely positioned to redefine the standard of care for patients with limited options, by suggesting an immune system remodeling—rather than mere symptom suppression—offering a potential path to true disease resolution. RESTEM is headquartered in Miami, Florida. For more information, please visit and follow us on X and LinkedIn. Investor Contact Daniel Ferry LifeSci Advisors +1.617.430.7576 daniel@ Media Contact Nelson CabautanRestem Group, Inc. +1.800.490.0924 ncabatuan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data